Portal de Periódicos da CAPES

Drug Formulary Restrictions as a Cost-Containment Policy in Medicaid Programs

1993; University of Chicago Press; Volume: 36; Issue: 1, Part 1 Linguagem: Inglês

10.1086/467265

1537-5285

William J. Moore, Robert J. Newman,

Pharmaceutical industry and healthcare

Previous articleNext article No AccessDrug Formulary Restrictions as a Cost-Containment Policy in Medicaid ProgramsWilliam J. Moore and Robert J. NewmanWilliam J. Moore and Robert J. NewmanPDFPDF PLUS Add to favoritesDownload CitationTrack CitationsPermissionsReprints Share onFacebookTwitterLinkedInRedditEmail SectionsMoreDetailsFiguresReferencesCited by The Journal of Law and Economics Volume 36, Number 1, Part 1Apr., 1993 Sponsored by The University of Chicago Booth School of Business and The University of Chicago Law School Article DOIhttps://doi.org/10.1086/467265 Views: 7Total views on this site Citations: 29Citations are reported from Crossref Copyright 1993 The University of ChicagoPDF download Crossref reports the following articles citing this article:Matthew Grennan, Ashley Swanson Bargaining in Healthcare Markets: Applications of Nash-in-Nash and Extensions, (Apr 2022): 249–270.https://doi.org/10.1007/978-3-030-76666-5_12James C. Cooper and Joseph Golec Conflicts of Interest on Committees of Experts: The Case of Food and Drug Administration Drug Advisory Committees, The Journal of Law and Economics 62, no.22 (Aug 2019): 321–346.https://doi.org/10.1086/703206S.J. Kim, K.-T. Han, H.-G. Kang, E.-C. Park Toward safer prescribing: evaluation of a prospective drug utilization review system on inappropriate prescriptions, prescribing patterns, and adverse drug events and related health expenditure in South Korea, Public Health 163 (Oct 2018): 128–136.https://doi.org/10.1016/j.puhe.2018.06.009Daniel Sutter The Political Economy of Medicaid Expansion: Federalism, Interest Groups, and the ACA, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3191450Robert K Arao, Michelle Y O'Connor, Thomas Barrett, Leela Chockalingam, Farrah Khan, Anirudh Kumar, Andrew Leader, Emily Leven, John R Power, Benjamin Shuham, Robert Rifkin, David Thomas, Yasmin Meah, Brijen J Shah Strengthening value-based medication management in a free clinic for the uninsured: Quality interventions aimed at reducing costs and enhancing adherence, BMJ Open Quality 6, no.22 (Oct 2017): e000069.https://doi.org/10.1136/bmjoq-2017-000069Pedro Raventós, Sandro Zolezzi Electronic tendering of pharmaceuticals and medical devices in Chile, Journal of Business Research 68, no.1212 (Dec 2015): 2569–2578.https://doi.org/10.1016/j.jbusres.2015.06.024Sara Parker-Lue, Michael Santoro, Greg Koski The Ethics and Economics of Pharmaceutical Pricing, Annual Review of Pharmacology and Toxicology 55, no.11 (Jan 2015): 191–206.https://doi.org/10.1146/annurev-pharmtox-010814-124649James D. Dana Buyer groups as strategic commitments, Games and Economic Behavior 74, no.22 (Mar 2012): 470–485.https://doi.org/10.1016/j.geb.2011.08.014Michael E. Schatman The Role of the Health Insurance Industry in Perpetuating Suboptimal Pain Management, Pain Medicine 12, no.33 (Mar 2011): 415–426.https://doi.org/10.1111/j.1526-4637.2011.01061.xEtienne E. Pracht, Elizabeth Bass Exploring the Link between Ambulatory Care and Avoidable Hospitalizations at the Veteran Health Administration, Journal for Healthcare Quality 33, no.22 (Mar 2011): 47–56.https://doi.org/10.1111/j.1945-1474.2010.00125.xSARA FISHER ELLISON, CHRISTOPHER M. SNYDER COUNTERVAILING POWER IN WHOLESALE PHARMACEUTICALS, The Journal of Industrial Economics 58, no.11 (Mar 2010): 32–53.https://doi.org/10.1111/j.1467-6451.2010.00408.xCarolyn M. Brown, Esmond Nwokeji, Karen L. Rascati, Woodie Zachry, Glenn A. Phillips Development of the Burden of Prior Authorization of Psychotherapeutics (BoPAP) Scale to Assess the Effects of Prior Authorization Among Texas Medicaid Providers, Administration and Policy in Mental Health and Mental Health Services Research 36, no.44 (Apr 2009): 278–287.https://doi.org/10.1007/s10488-009-0220-4Kosali Simon, Sharon Tennyson, Julie Hudman Do State Cost Control Policies Reduce Medicaid Prescription Drug Spending?, Risk Management and Insurance Review 12, no.11 (Mar 2009): 39–66.https://doi.org/10.1111/j.1540-6296.2009.01153.xSHARON TENNYSON, HAE KYUNG YANG State Prescription Drug Policies, Cost Barriers, and the Use of Acute Care Services by Medicaid Beneficiaries, Journal of Consumer Affairs 43, no.11 (Feb 2009): 4–25.https://doi.org/10.1111/j.1745-6606.2008.01125.xSule Akkoyunlu, Frank R. Lichtenberg, Boriss Siliverstovs, Peter Zweifel Spurious Correlation in Estimation of the Health Production Function: A Note, SSRN Electronic Journal (Jan 2009).https://doi.org/10.2139/ssrn.1402706James D. Dana Buyer Groups as Strategic Commitments, SSRN Electronic Journal (Jan 2009).https://doi.org/10.2139/ssrn.1504211Seok-Woo Kwon Does the Standardization Process Matter? A Study of Cost Effectiveness in Hospital Drug Formularies, Management Science 54, no.66 (Jun 2008): 1065–1079.https://doi.org/10.1287/mnsc.1070.0839Jonathan D. Ketcham, Andrew J. Epstein Medicaid Preferred Drug Lists' Costs to Physicians, Medical Care 46, no.11 (Jan 2008): 9–16.https://doi.org/10.1097/MLR.0b013e31814b8245Sanjoy Roy, S Suresh Madhavan Making a Case for Employing a??Societal Perspective in the Evaluation??of Medicaid Prescription??Drug Interventions, PharmacoEconomics 26, no.44 (Jan 2008): 281–296.https://doi.org/10.2165/00019053-200826040-00002William J. Moore, Etienne E. Pracht Changes in the Effectiveness of State Medicaid Drug Program Cost-Containment Policies Following OBRA 1990, American Journal of Economics and Sociology 66, no.55 (Dec 2007): 901–924.https://doi.org/10.1111/j.1536-7150.2007.00546.xAlan D. Schmetzer, John J. Wernert Point–Counterpoint: The Importance of "Open Access" to Psychotropics for our Patients, Psychiatric Quarterly 77, no.44 (Aug 2006): 329–334.https://doi.org/10.1007/s11126-006-9018-7Haiden A. Huskamp, Richard G. Frank, Kimberly A. McGuigan, Yuting Zhang The Impact of a Three-Tier Formulary on Demand Response for Prescription Drugs, Journal of Economics Management Strategy 14, no.33 (Sep 2005): 729–753.https://doi.org/10.1111/j.1530-9134.2005.00080.xSoonman Kwon Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing, Social Science & Medicine 57, no.33 (Aug 2003): 529–538.https://doi.org/10.1016/S0277-9536(02)00378-7Etienne E. Pracht, William J. Moore Interest Groups and State Medicaid Drug Programs, Journal of Health Politics, Policy and Law 28, no.11 (Feb 2003): 9–40.https://doi.org/10.1215/03616878-28-1-9Sara Fisher Ellison, Christopher M. Snyder Countervailing Power in Wholesale Pharmaceuticals, SSRN Electronic Journal (Jan 2001).https://doi.org/10.2139/ssrn.277290F.M. Scherer Chapter 25 The pharmaceutical industry, (Jan 2000): 1297–1336.https://doi.org/10.1016/S1574-0064(00)80038-4Karel Cool, Lars-Hendrik Röller, Benoit Leleux The relative impact of actual and potential rivalry on firm profitability in the pharmaceutical industry, Strategic Management Journal 20, no.11 (Jan 1999): 1–14.https://doi.org/10.1002/(SICI)1097-0266(199901)20:1<1::AID-SMJ995>3.0.CO;2-XFrank A Sloan, Kathryn Whetten-Goldstein, Alicia Wilson Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis, Social Science & Medicine 45, no.44 (Aug 1997): 523–533.https://doi.org/10.1016/S0277-9536(96)00393-0M. Torralba Guirao, N. Casals Farre, M. Calero García, R. Morera Castell, J.L. Segu Tolsa, M. López Marín La Prescripción Farmacéutica en Cataluña tras, el Decreto de Financiación Selectiva de Medicamentos, Gaceta Sanitaria 10, no.5555 (Jan 1996): 183–190.https://doi.org/10.1016/S0213-9111(96)71894-0